Zegalogue FDA Approval History
FDA Approved: Yes (First approved March 22, 2021)
Brand name: Zegalogue
Generic name: dasiglucagon
Dosage form: Injection
Company: Zealand Pharma A/S
Treatment for: Hypoglycemia
Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older.
- Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels. It is associated primarily with insulin therapy. Dasiglucagon works by increasing blood glucose concentration through activation of hepatic glucagon receptors, thereby stimulating glycogen breakdown, and release of glucose from the liver.
- Zegalogue is available as a single-dose autoinjector and a single-dose prefilled syringe. Zegalogue is administered via subcutaneous injection into the lower abdomen, buttocks, thigh, or outer upper arm. Caregivers should call for emergency assistance immediately after administering the dose.
- Common adverse reactions in adults include nausea, vomiting, headache, diarrhea and injection site pain. Common adverse reactions in children include nausea, vomiting, headache and injection site pain.
Development Timeline for Zegalogue
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.